DNTH
Dianthus Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +10.0% ·
share flow +3.0% ·
net new positions +9.1%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 96 | +12 | 36.60M | $3.56B | +16 | −4 |
| Q1 2026 | 87 | +18 | 31.37M | $2.59B | +21 | −3 |
| Q4 2025 | 69 | +2 | 26.03M | $1.07B | +3 | −1 |
| Q3 2025 | 16 | +2 | 17.27M | $679.58M | +2 | — |
| Q2 2025 | 11 | +1 | 11.18M | $208.23M | +1 | — |
| Q1 2025 | 7 | -2 | 3.50M | $63.53M | — | −2 |
| Q4 2024 | 9 | -1 | 2.27M | $49.52M | +1 | −2 |
| Q3 2024 | 9 | +3 | 1.20M | $32.83M | +4 | −1 |
| Q2 2024 | 6 | — | 1.13M | $29.26M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 4.54M | — | $84.66M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Fidelity (FMR) ✦ | 4.54M | — | $84.66M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Fidelity (FMR) ✦ | 4.54M | — | $84.66M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | The Vanguard Group ✦ (passive) | 1.45M | — | $26.94M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | The Vanguard Group ✦ (passive) | 1.45M | — | $26.94M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | The Vanguard Group ✦ (passive) | 1.45M | — | $26.94M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Point72 Asset Management ✦ | 1.39M | -6.3% | $25.94M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 8 | BlackRock ✦ (passive) | 1.36M | — | $25.31M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | BlackRock ✦ (passive) | 1.36M | — | $25.31M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | BlackRock ✦ (passive) | 1.36M | — | $25.31M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | BlackRock ✦ (passive) | 1.36M | — | $25.31M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | BlackRock ✦ (passive) | 1.36M | — | $25.31M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | BlackRock ✦ (passive) | 1.36M | — | $25.31M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | BlackRock ✦ (passive) | 1.36M | — | $25.31M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | State Street Global Advisors ✦ (passive) | 820.14K | +8.0% | $15.28M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 665.04K | +41.2% | $12.39M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 665.04K | +41.2% | $12.39M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 18 | Geode Capital Management ✦ (passive) | 484.90K | -6.2% | $9.04M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 19 | Geode Capital Management ✦ (passive) | 484.90K | -6.2% | $9.04M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 20 | Millennium Management ✦ | 195.36K | New | $3.64M | 0.0% | New | 1 | SEC ↗ |
| 21 | Adage Capital Partners ✦ | 185.00K | -2.1% | $3.45M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 22 | Wellington Management ✦ | 74.35K | +9.4% | $1.39M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 23 | Wellington Management ✦ | 74.35K | +9.4% | $1.39M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 24 | Wellington Management ✦ | 74.35K | +9.4% | $1.39M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 25 | T. Rowe Price ✦ | 10.69K | +1.9% | $200,000 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Millennium Management | $3.64M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 240 holders, 62.10M shares, $4.94B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 2.78K sh · $326,554
Director · 737 sh · $79,721
Director · 831 sh · $90,537
Director · 272 sh · $29,909
Director · 470 sh · $52,194
Director · 397 sh · $44,373
Director · 700 sh · $77,987
Director · 70 sh · $7,498
Director · 2.80K sh · $303,464
Director · 1.80K sh · $196,740
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology